Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Identification of Key Blood Molecular Markers for Immunotherapy
This study is currently recruiting participants.
Verified by Stanford University, July 2007
Sponsored by: Stanford University
Information provided by: Stanford University
ClinicalTrials.gov Identifier: NCT00507702
  Purpose

To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.


Condition
Cancer

MedlinePlus related topics: Cancer
U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Cross-Sectional, Defined Population, Prospective Study
Official Title: Identification of Key Blood Molecular Markers for Immunotherapy
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Patients diagnosed with cancerous tumors based on biopsy or other clinical observations.
  2. Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations.
  3. Normal volunteers who do not have cancer or other medical conditions that may affect survival.

Exclusion Criteria:

  1. Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the inmmune response against tumors.
  2. Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings msy be altered.
  3. Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00507702

Contacts
Contact: Robin M Cisco 650-723-5570 rcisco@stanford.edu

Locations
United States, California
Stanford University Cancer Center Recruiting
Stanford, California, United States, 94305
Contact: Stanford Cancer Clinical Trials Office     650-498-7061        
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Jeffrey Norton, M.D. Stanford University
  More Information

Study ID Numbers: VAR0017
Study First Received: July 24, 2007
Last Updated: July 25, 2007
ClinicalTrials.gov Identifier: NCT00507702  
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on January 16, 2009